Al Alphatec Holdings, Inc. and Theradaptive, Inc. announced a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platform across global therapeutic applications. Under the terms of the agreement, ATEC gains exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt®?
osteoinductive bone graft for spinal fusion. This represents a landmark regenerative medicine partnership for the spine industry, structured to deliver significant long-term value through a combination of upfront and milestone payments and a perpetual royalty structure. Leveraging proprietary AMP2??
protein technology, OsteoAdapt is currently being evaluated in clinical trials in spine and dental applications and is subject to FDA PMA approval. The technology has received three FDA Breakthrough Device Designations, underscoring its potential to address significant unmet medical needs in bone regeneration. Theradaptive Series B Financing Initiation: To support the completion of clinical studies and rapid scaling of its technology platform alongside the ATEC partnership, Theradaptive has launched a Series B investment round.
This capital will facilitate the advancement of the OASIS Pivotal trial in spinal fusion and the manufacturing scale-up and build-out in support of future commercialization. Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity. OsteoAdapt's targeted approach represents a paradigm shift intended to make traditional allograft and synthetic alternatives obsolete.
The sustained sales growth from ATEC's sales force provides confidence in maximizing market penetration and returning value to Theradaptive with the ongoing royalties.
